SPRAVATO (esketamine HCl)
ANTIDEPRESSANT NMDA RECEPTOR ANTAGONISTS · MAJOR DEPRESSIVE DISORDER ·+1
JANSSEN PHARM.
Drug class
Antidepressant NMDA Receptor Antagonists
While the exact phrase "Antidepressant NMDA Receptor Antagonists" is a functional grouping rather than a formal, standalone Established Pharmacologic Class designation by regulatory agencies, it describes a modern class of psychotropic medications that modulate glutamatergic signaling to treat mood disorders. Read more about Antidepressant NMDA Receptor Antagonists
1 drugs in this class 1 manufacturers
Drugs in Antidepressant NMDA Receptor Antagonists
Filter & compare in the drug finder →
Opens the drug finder with Antidepressant NMDA Receptor Antagonists preselected. Add indication or manufacturer filters there.
While the exact phrase "Antidepressant NMDA Receptor Antagonists" is a functional grouping rather than a formal, standalone Established Pharmacologic Class designation by regulatory agencies, it describes a modern class of psychotropic medications that modulate glutamatergic signaling to treat mood disorders.
These agents exert their therapeutic effect primarily by noncompetitively or uncompetitively blocking N-methyl-D-aspartate (NMDA) receptors, which triggers downstream synaptic plasticity, enhances AMPA receptor activation, and promotes neurotrophic signaling.
Clinically, members of this therapeutic category—such as esketamine and dextromethorphan in combination regimens—are indicated for major depressive disorder and treatment-resistant depression, offering a rapid-acting alternative to conventional monoaminergic antidepressants.
-
nih.gov
While the exact phrase "Antidepressant NMDA Receptor Antagonists" is a functional grouping rather than a formal, standalone Established Pharmacologic Class designation by regulatory agencies, it describes a modern class of psychotropic medications that modulate glutamatergic signaling to treat mood disorders
-
fda.gov
While the exact phrase "Antidepressant NMDA Receptor Antagonists" is a functional grouping rather than a formal, standalone Established Pharmacologic Class designation by regulatory agencies, it describes a modern class of psychotropic medications that modulate glutamatergic signaling to treat mood disorders
-
policylab.us
These agents exert their therapeutic effect primarily by noncompetitively or uncompetitively blocking N-methyl-D-aspartate (NMDA) receptors, which triggers downstream synaptic plasticity, enhances AMPA receptor activation, and promotes neurotrophic signaling
-
nih.gov
These agents exert their therapeutic effect primarily by noncompetitively or uncompetitively blocking N-methyl-D-aspartate (NMDA) receptors, which triggers downstream synaptic plasticity, enhances AMPA receptor activation, and promotes neurotrophic signaling
-
fda.gov
These agents exert their therapeutic effect primarily by noncompetitively or uncompetitively blocking N-methyl-D-aspartate (NMDA) receptors, which triggers downstream synaptic plasticity, enhances AMPA receptor activation, and promotes neurotrophic signaling Clinically, members of this therapeutic category—such as esketamine and dextromethorphan in combination regimens—are indicated for major depressive disorder and treatment-resistant depression, offering a rapid-acting alternative to conventio...
-
agoramedia.com
Clinically, members of this therapeutic category—such as esketamine and dextromethorphan in combination regimens—are indicated for major depressive disorder and treatment-resistant depression, offering a rapid-acting alternative to conventional monoaminergic antidepressants
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.